Back to Journals » Drug Design, Development and Therapy » Volume 9

Neuroprotective therapies for glaucoma

Authors Song W, Huang P, Zhang C

Received 8 January 2015

Accepted for publication 5 February 2015

Published 11 March 2015 Volume 2015:9 Pages 1469—1479

DOI https://doi.org/10.2147/DDDT.S80594

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Editor who approved publication: Professor Wei Duan

Wei Song, Ping Huang, Chun Zhang

Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China

Abstract: Glaucoma is the second leading cause for blindness worldwide. It is mainly caused by glaucomatous optic neuropathy (GON) characterized by retinal ganglion cell loss, which leads to visual field defect and blindness. Up to now, the main purpose of antiglaucomatous therapies has been to lower intraocular pressure (IOP) through surgeries and medications. However, it has been found that progressive GON is still present in some patients with effective IOP decrease. Therefore, risk factors other than IOP elevation, like neurotrophin deprivation and excitotoxicity, contribute to progressive GON. Novel approaches of neuroprotection may be more effective for preserving the function of the optic nerve.

Keywords: glaucoma, glaucomatous optic neuropathy, retinal ganglion cells, neuro­protection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Predicting frequent COPD exacerbations using primary care data

Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2439-2450

Published Date: 9 November 2015

Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles

Yong CY, Yeap SK, Ho KL, Omar AR, Tan WS

International Journal of Nanomedicine 2015, 10:2751-2763

Published Date: 2 April 2015

Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses

Xie Z, Qu Y, Leng Y, Sun W, Ma S, Wei J, Hu J, Zhang X

Drug Design, Development and Therapy 2015, 9:1679-1689

Published Date: 18 March 2015

Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer

Hou CP, Lee WC, Lin YH, Chen SM, Chen CL, Chang PL, Juang HH, Tsui KH

OncoTargets and Therapy 2015, 8:15-19

Published Date: 17 December 2014

Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer

Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, Bryan JN, Henry CJ, Boote E, Tate DJ, Bryan ME, Katti KV, Kannan R

International Journal of Nanomedicine 2014, 9:5001-5011

Published Date: 28 October 2014

Nanopharmaceuticals (part 1): products on the market

Weissig V, Pettinger TK, Murdock N

International Journal of Nanomedicine 2014, 9:4357-4373

Published Date: 15 September 2014

Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD

Moraes MR, da Costa AC, Corrêa KS, Junqueira-Kipnis AP, Rabahi MF

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:735-743

Published Date: 29 July 2014

Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery

Lee CH, Lin YH, Chang SH, Tai CD, Liu SJ, Chu Y, Wang CJ, Hsu MY, Chang H, Chang GJ, Hung KC, Hsieh MJ, Lin FC, Hsieh IC, Wen MS, Huang Y

International Journal of Nanomedicine 2014, 9:311-326

Published Date: 6 January 2014

Glimepiride: evidence-based facts, trends, and observations

Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2012, 8:463-472

Published Date: 15 August 2012

Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch

Chen CH, Lin YL, Liu YK, He PJ, Lin CM, Chiu YH, Wu CJ, Cheng TL, Liu SJ, Liao KW

International Journal of Nanomedicine 2012, 7:607-621

Published Date: 3 February 2012